Effect of flosequinan on exercise capacity and symptoms in severe heart failure.

Elborn, J. Stuart; Stanford, C. F.; Nicholls, D. P.

doi:10.1136/hrt.61.4.331

Cited by 49 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21][22][23] The present study was undertaken to determine whether the addition of oral flosequinan increases exercise time and improves the quality of life in patients who are maintained on a regimen including diuretics, digoxin, and an angiotensin converting enzyme inhibitor.…”

mentioning

confidence: 99%

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

et al. 1993

View full text Add to dashboard Cite

Background. Angiotensin converting enzyme inhibitors, diuretics, and digoxin are each effective in treating congestive heart failure, but many patients remain symptom-limited on all three medications. This trial was designed to determine whether the addition of oral flosequinan, a new direct-acting arterial and venous vasodilator with possible dose-dependent positive inotropic effects, improves exercise tolerance and quality of life in such patients.Methods and Results. In a randomized, double-blind multicenter trial, 322 patients with predominantly

show abstract

mentioning

confidence: 99%

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

et al. 1993

View full text Add to dashboard Cite

show abstract

“…There are no previous reports of the effects of flosequinan on exercise haemodynamics. Two previous studies have demonstrated improved exercise tolerance in response to flosequinan following 7 days treatment [19] and following 8 weeks chronic treatment [17] although in the latter study the timing in relation to previous dosing is unclear.…”

Section: Discussionmentioning

confidence: 83%

“…Further acute haemodynamic studies in patients with heart failure have shown significant resting haemodynamic effects up to 24 h post dose [14,15]. In non-invasive studies of patients with chronic congestive heart failure, flosequinan has been shown to improve exercise tolerance after 4 [15] and 8 weeks treatment [17]. No Three constrast variables, phase, treatment and time (pre-exercise, 3 min and 6 min during exercise) were used to analyse data from the bicycle exercise tests, again using a repeated measures model.…”

Section: Introductionmentioning

confidence: 99%

Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure

Thomas

O'gorman

Sheridan

1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…In single dose and short-term administration, flosequinan has been reported to improve resting hemodynamics in patients with chronic heart failure [5][6][7]. This drug has been also reported to increase the exercise time, peak oxygen uptake and anaerobic threshold with short-term administration in patients with severe heart failure [8][9][10]. Thus the drug appears to be promising as a vasodilator which can promptly improve exercise capacity.…”

Section: Introductionmentioning

confidence: 89%

“…107.2" 9) 1.7 (9) 1.4" (7) (lO) (10) Figures in parentheses represent number of subjects (n) * P < 0.05 versus final evaluation of run-in period Data are expressed as mean ___ SE CTR, cardiothoracic ratio; EDD, end-diastolic dimension; ESD, end-systolic dimension; FS, fractional shortening; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; ET, exercise time; VOzsymp, oxygen uptake at the end of symptom-limited exercise; VO2AT, oxygen uptake at anaerobic threshold; NYHA, New York Heart Association; HF, heart failure placebo was judged superior, the patients treated with ftosequinan (nos. 5 and 19) dropped out due to exacerbation of heart failure or adverse effects.…”

Section: )mentioning

confidence: 99%

Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: A double-blind placebo-controlled study

et al. 1992

View full text Add to dashboard Cite

Although beneficial effects of a new vasodilating agent, flosequinan, have been demonstrated in patients with severe heart failure, its efficacy has not been studied in patients with a less severe form of chronic heart failure. In this study, the effects of 4 weeks' administration of flosequinan, 50 mg daily, and placebo on exercise capacity, cardiac function, and symptoms of heart failure were investigated in 24 patients with chronic mild heart failure (New York Heart Association functional class, mainly class II) in a double-blind clinical trial. When the parameter changes during the treatment period of the flosequinan and placebo groups were compared, no significant difference was found in any of the measurements except for left ventricular fractional shortening determined from M-mode echocardiograms; it was increased by 2.9 +/- 1.3% in the flosequinan group whereas it was decreased by 1.3 +/- 0.9% in the placebo group (P less than 0.05 vs flosequinan treatment). However, when compared to baseline values, flosequinan significantly increased exercise time in the symptom-limited maximal exercise test (704 +/- 103 to 763 +/- 107 s, P less than 0.05) and the oxygen uptake at the anaerobic threshold (13.8 +/- 1.3 to 16.7 +/- 1.4 ml/min kg, P less than 0.05), and improved symptoms assessed with a new heart failure severity classification (a median value of 2.0-1.5, P less than 0.05). These improvements were not observed in the placebo group. Serious adverse effects were not observed in either group. These results suggest that flosequinan is useful for the treatment of chronic mild heart failure as well as severe heart failure.

show abstract

Effect of flosequinan on exercise capacity and symptoms in severe heart failure.

Cited by 49 publications

References 16 publications

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure

Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: A double-blind placebo-controlled study

Contact Info

Product

Resources

About